| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1600-6143.2007.01991.X |
| P698 | PubMed publication ID | 17908268 |
| P50 | author | Iman M Hamour | Q79924696 |
| P2093 | author name string | Rose ML | |
| Smith JD | |||
| Banner NR | |||
| P2860 | cites work | Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers | Q34342506 |
| Acute antibody-mediated rejection of cardiac transplants | Q36381735 | ||
| Flow cytometry based detection of HLA alloantibody mediated classical complement activation. | Q40597066 | ||
| Flow cytometric detection of HLA antibodies using a spectrum of microbeads | Q40907524 | ||
| Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification | Q44919347 | ||
| [C4d]FlowPRA screening--a specific assay for selective detection of complement-activating anti-HLA alloantibodies. | Q51443894 | ||
| Microdroplet Assay of Human Serum Cytotoxins | Q59059757 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 2809-2815 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation | |
| P478 | volume | 7 |
| Q28383579 | A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239 |
| Q38818993 | Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside |
| Q42126102 | Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. |
| Q28076193 | Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q54589598 | Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs. |
| Q33568195 | Bead arrays for antibody and complement profiling reveal joint contribution of antibody isotypes to C3 deposition |
| Q42913151 | Bortezomib: a new player in pre- and post-transplant desensitization? |
| Q37263143 | C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch |
| Q82659907 | C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation |
| Q38363600 | Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient |
| Q52586350 | Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. |
| Q39015291 | Clinical and immunological relevance of antibodies in solid organ transplantation |
| Q47880758 | Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? |
| Q48371099 | Clinical utility of C3d binding donor-specific anti-human leukocyte antigen antibody detection by single antigen beads after kidney transplantation-a retrospective study. |
| Q45930637 | Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. |
| Q41514316 | Correlation of Pretransplant Donor-specific Antibody Assay Using Luminex Crossmatch with Graft Outcome in Renal Transplant Patients |
| Q87107009 | Desensitization Strategies Pre- and Post-Cardiac Transplantation |
| Q26998713 | Detection and clinical relevance of donor specific HLA antibodies: a matter of debate |
| Q35027253 | Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. |
| Q28075921 | Detection of HLA Antibodies in Organ Transplant Recipients - Triumphs and Challenges of the Solid Phase Bead Assay |
| Q38204851 | Detection of donor-specific antibodies in kidney transplantation |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q45106203 | Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies |
| Q47749267 | Donor-specific anti-HLA antibodies detected by Luminex: predictive for short-term but not long-term survival after heart transplantation |
| Q36554486 | Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study |
| Q37653182 | Easy identification of antibodies to high-prevalence Scianna antigens and detection of admixed alloantibodies using soluble recombinant Scianna protein |
| Q42223600 | Eosinophils are not required for the induction and maintenance of an alloantibody response |
| Q36043667 | Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells |
| Q44274789 | Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients |
| Q35073502 | High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation |
| Q37418386 | Histocompatibility methods. |
| Q38246225 | Human leukocyte antigens and alloimmunization in heart transplantation: an open debate |
| Q38341785 | Humoral immunity in renal transplantation: epitopes, Cw and DP, and complement-activating capability--an update |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q92033719 | Impact of pretransplant antibodies on outcomes after heart transplantation |
| Q38032621 | Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. |
| Q34309101 | Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients. |
| Q38007085 | Luminex and antibody detection in kidney transplantation |
| Q33409582 | Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion |
| Q45821566 | Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection. |
| Q90537689 | Measuring alloreactive B cell responses in transplant recipients |
| Q43461676 | Meeting report: 2nd international conference: antibody incompatible transplantation and transplant infectious disease |
| Q38267906 | Methods for the selection of platelet products for alloimmune-refractory patients |
| Q84456399 | Minimising the clinical impact of the alloimmune response through effective histocompatibility testing for organ transplantation |
| Q53187406 | Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays? |
| Q40310759 | Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance. |
| Q35574072 | Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching |
| Q84973210 | On solid-phase antibody assays |
| Q51764178 | Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation. |
| Q36708983 | Regulation of allograft survival by inhibitory FcγRIIb signaling |
| Q37414657 | Report from a consensus conference on the sensitized patient awaiting heart transplantation |
| Q91662983 | Role of complement in patients with autoimmune hemolytic anemia and platelet transfusion refractoriness |
| Q30317554 | Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes |
| Q88656410 | The Approach to Antibodies After Heart Transplantation |
| Q50042370 | The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation |
| Q38036750 | The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera |
| Q44940147 | The interplay of donor-specific antibodies, allograft C4d deposition, and antibody-mediated rejection |
| Q48305003 | The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation. |
| Q38542338 | Transplant immuno-diagnostics: crossmatch and antigen detection |
| Q37754549 | Trends in HLA antibody screening and identification and their role in transplantation. |
| Q39144570 | Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review. |
| Q37808761 | Virtual crossmatch approach to maximize matching in paired kidney donation |
| Q34761349 | What's new in clinical solid organ transplantation by 2013. |
Search more.